Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger and CHY zinc finger domain containing 1 (RCHY1)
- Target
- RCHY1
- Molecular classification
- E3 ubiquitin-protein ligase, RING finger protein, CHY zinc finger protein, Enzyme, Protein family: RING-type E3 ubiquitin ligases
01
Overview
Ring finger and CHY zinc finger domain containing 1 (RCHY1) is an E3 ubiquitin ligase that facilitates the ubiquitination and proteasomal degradation of target proteins including p53, HDAC1, CDKN1B, and TP73. It is a short-lived, nuclear-localized protein subject to self-ubiquitination and degradation, and it plays critical roles in the regulation of cell cycle progression, DNA damage response, and protein quality control. RCHY1 interacts with various transcription factors (notably HOX family proteins), and its dysregulation is implicated in cancer, where it can modulate the stability of key tumor suppressors. RCHY1 is being studied as a potential therapeutic target, particularly for cancers characterized by aberrant ubiquitin-mediated degradation of p53
- Other names
- PIRH2ZN363RCHY1
02
Mechanism of action
Drugs theoretically targeting RCHY1 would act by inhibiting its E3 ligase activity; reducing ubiquitination and degradation of tumor suppressor proteins like p53, leading to increased tumor suppressor function and decreased proliferation
03
Biological functions
Ubiquitination of target proteins (including p53, HDAC1, CDKN1B, TP73, POLH)Proteasome-dependent protein degradationRegulation of cell cycle progressionDNA damage responseRibosome-associated quality control (RQC) of stalled nascent chainsCell proliferation and cell death regulation
04
Disease associations
Cancer (regulates tumor suppressors such as p53; implicated in carcinogenesis and tumor progression)Geroderma osteodysplasticum (genetic disorder associated with mutations in RCHY1)
05
Safety considerations
Potential safety challenges may include off-target effects on protein degradation pathways and cell cycle regulation; inhibition could impact normal cellular turnover and apoptosis, requiring selective targeting
06
Biomarkers
RCHY1 expression and/or activity could serve as a biomarker of p53 pathway activity, cell cycle dysregulation, or proteasomal/ubiquitin-pathway dysfunction, especially in cancer contexts
Beyond the preview
Go deeper on Ring finger and CHY zinc finger domain containing 1 (RCHY1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ring finger and CHY zinc finger domain containing 1 (RCHY1).